Pancreatic Beta Cell Therapy Market

Stem cell-derived beta cell therapy is projected to lead the pancreatic beta cell therapy market at 43.5% share in 2026, followed by type 1 diabetes as anticipated to represent 41.2% share of indication in 2026. Adoption depends on reproducible cell production and durable graft function, with chronic immunosuppression and limited reimbursement forming principal barriers.